Powder: -20°C for 3 years | In solvent: -80°C for 1 year
K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 347 | 现货 | ||
2 mg | ¥ 490 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,480 | 现货 | ||
50 mg | ¥ 3,480 | 现货 | ||
100 mg | ¥ 4,870 | 现货 | ||
500 mg | ¥ 9,830 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 892 | 现货 |
产品描述 | K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes. |
体外活性 | K6PC-5 (1-10 μM; 24 h) increases the involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs). K6PC-5 promotes differentiation and proliferation of keratinocytes via intracellular Ca2+ signaling. In addition, K6PC-5 stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase[1]. K6PC-5 (1-10 μM; 24 h) promotes fibroblasts proliferation and collagen synthesis in human fibroblasts. K6PC-5 induces intracellular Ca2+ concentration ([Ca2+]i) oscillations in human fibroblasts[2]. K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV-induced infection in EBOV-infected EA.hy926 cells. K6PC-5 significantly reduces the virus titers in supernatants of infected cells and strikingly decreased the amount of VP40 in a concentration-dependent manner[3]. |
体内活性 | 在本质上老化的无毛小鼠(56周岁)中,1%的K6PC-5被局部应用2周。这种K6PC-5处理显著增加了真皮成纤维细胞的数量和胶原蛋白的产生。因此,真皮厚度也显著增加[2]。 |
别名 | K6PC5, K6PC 5 |
分子量 | 343.5 |
分子式 | C19H37NO4 |
CAS No. | 756875-51-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (262 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9112 mL | 14.556 mL | 29.1121 mL | 72.7802 mL |
5 mM | 0.5822 mL | 2.9112 mL | 5.8224 mL | 14.556 mL | |
10 mM | 0.2911 mL | 1.4556 mL | 2.9112 mL | 7.278 mL | |
20 mM | 0.1456 mL | 0.7278 mL | 1.4556 mL | 3.639 mL | |
50 mM | 0.0582 mL | 0.2911 mL | 0.5822 mL | 1.4556 mL | |
100 mM | 0.0291 mL | 0.1456 mL | 0.2911 mL | 0.7278 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
K6PC-5 756875-51-1 GPCR/G Protein S1P Receptor K6PC5 K6PC 5 Inhibitor inhibitor inhibit